Browsing by Author "Cavagnaro, F."

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Congenital hepatic fibrosis. Report of five cases.
    (2004) Harris, Paul R.; Fodor, D.; Cavagnaro, F.; Di Egidio, M.; Duarte, I.; Fava, M.
    Background. Congenital hepatic fibrosis (CHF) is an autosomic dominant disease that has been associated with polycystic kidney disease. Aim: To describe the medical management of 5 children with CHF and to evaluate the presence and extension of the associated renal disease. Patients and methods: Retrospective review of the medical charts of 5 children with CHF, aged 2 to 14 years. Results: Three children presented autosomic recessive polycystic kidney disease, which was diagnosed before the appearance of liver disease manifestations. They presented a more severe liver damage, with a more aggressive clinical course requiring use of transjugular intrahepatic porto-systemic shunts (TIPS) or surgical porto-systemic shunts to control portal hypertension. The other two children, in whom the diagnosed was based on asymptomatic hepatomegaly, had normal renal function and structure with a more benign clinical course. Conclusions: The diagnosis of CHF should be suspected not only in children with polycystic kidney disease but in those children with persistent, hard consistency, left lobe predominance hepatomegaly.
  • Thumbnail Image
    Item
    Continuous renal replacement therapy in neonates and young infants during extracorporeal membrane oxygenation
    (SAGE PUBLICATIONS LTD, 2007) Cavagnaro, F.; Kattan, J.; Godoy, L.; Gonzalez, A.; Vogel, A.; Rodriguez, J. I.; Faunes, M.; Fajardo, C.; Becker, P.
    Extracorporeal membrane oxygenation (ECMO) is a therapy that ensures adequate tissue oxygen delivery in patients suffering cardiac and/or respiratory failure that are unresponsive to conventional therapy. During ECMO, it is common to see a decrease in urine output that may be associated with acute renal failure. In this context, continuous renal replacement therapy (CRRT) should be considered. Our aim is to evaluate a pioneer experience in Latin America, related to the use of CRRT in a group of neonatal-pediatric patients during ECMO. We conducted a retrospective review of patients treated with ECMO at our institution between May 2003 and May 2005. Twelve infants were treated with ECMO, six of them also underwent CRRT The main reasons for CRRT initiation were fluid overload and progressive azotemia. Observed complications were clots in the filter and excessive ultraffitration. CRRT was successful in fluid management and solute clearance in all patients. Discharge survival rate was 83%, all of them with normal renal function. Concurrent CRRT with ECMO is technically feasible and efficacious in the management of fluid overload and solute clearance. We report the first experience with these therapies in a Latin American neonatalpediatric ECMO program associated with the Extracorporeal Life Support Organization.
  • Thumbnail Image
    Item
    Fibrosis Hepática congénita: un espectro clínico variable: Casos clínicos
    (2004) Harris, Paul R.; Fodor, D.; Cavagnaro, F.; Di Egidio, M.; Fava, M.
    Background: Congenital hepalic fibrosis (CHF) is an autosomic dominant disease that has been associated will polycistic kidney disease. Aim. To describe The medical managment of 5 children with CHF and to evaluate the presence and extension of the associated renal disease. Patients and methods. Retrospective review of the medical charts of 5 children with CHF aged 2 to 14 years. Results: Three children presented autosomic recessive polycistic kidney disease, which was diagnosed before the appearance of liver disease manifestations. They presented a more severe liver damage with a more aggressive clinical course requiring use of transjugular intrahepatic porto-systemic shunts (TIPS) or surgical porto-systemic shunts to control portal hypertension. The other two children, in whom the diagnosed was based on asymptomatic hepatomegaly had normal renal function and structure with a more benign clinical course. Conclusions: The diagnosis of CHT should be suspected not only in children with polycystic kidney disease but in those children with persistent, hard consistently, left lobe predominance hepatomegaly.
  • No Thumbnail Available
    Item
    Latin American Registry of Pediatric Renal Transplantation 2004-2008
    (2010) Goulart, P.; Koch, P.; Medina-Pestana, J.; Garcia, C.; Bittencourt, V.; Medeiros, M.; Munoz, R.; Delucchi, A.; Lillo, A. M.; Ariza, M.; Bosque, M.; Carvalho, D.; Matuck, T.; Meneses, R.; Fontes, J.; Monteiro, D. C.; Neto, E. Davi; Pinto, V.; Salas, P.; Prates, L.; Belanguero, V.; Pereira, L.; Lima, E.; Penido, J. M.; Benini, V.; Laranjo, S.; Silva, J. M.; Orta, N.; Coronel, V.; Cisneros, A.; Arriaga, J.; Sebastian, M. J.; Abbud-Filho, M.; Fernandez, I.; Gastelbondo, R.; Medjia, N.; Rosati, P.; Hevia, P.; Baptista, M. A.; Ramalho, H.; Diaz, M.; Monteverde, M.; Ferraris, J.; Repetto, H.; Exeni, R.; Florentin, L.; Florin, J.; Cazorla, N.; Casadei, D.; Melendez, K.; Calderon, R.; Silva, V.; Patino, J.; Palacio, D.; Madrigal, G.; Sandoval, M.; Urbina, C.; Loza, R.; Cavagnaro, F.; Vogel, A.; Jimenez, W.; Lou, R.; Rodriguez, C.; Aguilar, C.; Galvez, H.; Rodriguez, L.; Paladini, J.; Agusti, J.; Puelma, F.; Troche, A.; Martinez-Pico, M.; Higueras, W.; Liendo, C.; Restrepo, J.; Caicedo, L. A.; Socorro, F.; Semprum, P.
    The Latin American Pediatric Nephrology Association (ALANEPE) reports the first regional kidney transplant registry in Latin America. A mean range of 75%, 30% to 100% renal transplant recipients under 21 yr old were included. Out of 20 countries invited to participate, 14 performed renal transplant, 11 had universal financial support from their governments. The centers included: Brazil (9), Argentina (4), Chile (4), Venezuela (3), Mexico (2), and one in: Cuba, Colombia, Costa Rica, Nicaragua, Guatemala, Ecuador, Honduras, Paraguay and Peru. The registry included 1458 patients, average of 291 per year, 55% male. Mean follow-up 23.4 +/- 17 months; mean age was 11.7 +/- 4.3 yr (1-21), 11% under five yr of age. Etiology: uropathy/ reflux nephropathy 27%, glomerulopathies 24% (included 12% FSGS), hypo/dysplasia (11%), vascular (6%), congenital/hereditary (5%), unknown (19%). Induction therapy: 71% anti-IL2RAb, 13% ATG/TIMO, 14% non-induction. Maintenance therapy: Tacrolimus 64%, Cyclosporine 32%, MMF 54%, MPS 20%, noTORi 96%, steroids 90%, withdrawal or steroid avoidance 10%. Loss of graft 155/1458 (11%), death with functioning graft (3.4%), vascular thrombosis (2.8%), acute rejection (2.8%), recurrence of disease (1%). Forty-eight patients died (3.3%); infection was the main cause 23 (2.1%). Global patient survival rate at one, three, and five yr was 97%, 96%, and 96%. Graft survival rate at one, three, and five yr LRD was 96%, 93% and 89%; for DD 92%, 86% and 76% respectively. Both survival rates were higher in LRD (p < 0.008 and p < 0.001). A pediatric renal transplant study has started, making information available to be shared between the centers and the world.